[U.S. Stocks Movement] Haleon plunged on October 29: Guidance lowered, Q3 weaker than expected, cold medicine demand subdued

Haleon October 29 Sharp Decline Interpretation

Keywords: Guidance Downgrade, Q3 Below Expectations, Weak Demand for Cold Medicine

1. On October 29, the company reported third-quarter revenue of £2.87 billion, below market expectations. The full-year organic revenue growth guidance was downgraded from 3%-5% to about 2.5%. Despite announcing a £500 million buyback on the same day, the pre-market share price still fell over 13%.

2. Disclosed on October 29, demand for cold and flu products was weaker than expected, with orders in North America declining, respiratory health revenue down 2%, and high single-digit decline in cold and flu consumption dragging the group by about 40 to 50 basis points.

3. Disclosed on October 29, some of China's Centrum OTC products stopped being imported due to changes in raw material classification, which dragged down third-quarter results by about 50 basis points. The company expects this issue will be difficult to resolve before 2027.

4. On October 29, the CEO stated in an employee memo that investment priorities are being reassessed and “difficult choices” will be made; European consumers are more focused on cost-effectiveness and are consuming inventory, leading to a slight decline in the cold and flu business year-to-date.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only; it does not constitute investment advice.)